Navigation Links
Evotec's Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
Date:3/26/2008

HAMBURG, Germany and OXFORD, England, March 26 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) announced today that the U.S. Securities and Exchange Commission (SEC) has declared effective Evotec's Registration Statement on Form F-4, which is required for the completion of the merger transaction with Renovis, Inc., a South San Francisco based biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. This is an important milestone in connection with the proposed acquisition by Evotec of all of the shares of Renovis as it is clearing the way for Renovis to call a stockholders' meeting to vote on the acquisition. Renovis has called a special stockholders' meeting for May 1, 2008 for that purpose.

The board of directors of Renovis and Evotec have approved the transaction and the board of directors of Renovis has recommended that its stockholders approve the transaction.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business combination transaction involving Evotec and Renovis, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information.
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
2. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
5. /CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
6. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
7. National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC
8. SyntheMed Files Universal Shelf Registration
9. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
10. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
11. Anacor Files Registration Statement for Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BioConvergence team members Curtis Strother and ... BioLogistics Summit in San Francisco earlier this month. ... IQ and IQPC, addressed the increasingly complex logistical ... attributed to current trends of globalization, outsourcing, and ... is an increase in movement, which is often ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of DrugCheck® ... has received Class III medical device license approval from ... NxStep Onsite Drug Screen Cup in Canada. Class ... in near-patient settings, such as physicians’ offices. , The ... Class III approval for 24 different drugs and detection ...
(Date:6/18/2013)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing, and stem ... results for the fourth quarter and full year of ... Fourth Quarter of Fiscal 2013 Highlights , ... by 33.3% to RMB133.0 million ($21.4 million) from RMB99.8 ...
(Date:6/18/2013)... Demanding industrial and environmental conditions are ... Sapphire and Glass Ball Lenses, now available in an ... Company , of Philadelphia , PA. , Optical Ball ... light beams without the need for direct physical contact. ... (9 mohs) make it the ideal choice for fiber-optic ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2
... 4, 2011 Sequenom, Inc. (NASDAQ: SQNM ... solutions, today announced the launch of its iPLEX ADME ... with drug absorption, distribution, metabolism, and excretion (ADME). This ... pre-designed single nucleotide polymorphisms (SNP), insertions and deletions (INDELS) ...
... OXFORD, England, October 4, 2011 PharmaVentures ... of Corporate Finance to significantly enhance Pharmaventures, advisory capabilities ... Fintan Walton, PhD, PharmaVentures, Chief Executive Office ... He brings a wealth of investment management experience and ...
... Calif., October 3, 2011 Glioblastoma is one of ... presenting as a well-defined tumor, glioblastoma will often infiltrate ... treat surgically or with chemotherapy or radiation. Likewise, several ... all treatment attempts. In a new study, a team ...
Cached Biology Technology:Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 3PharmaVentures Appoints Andy Smith as Head of Corporate Finance 2Nanoparticles seek and destroy glioblastoma in mice 2Nanoparticles seek and destroy glioblastoma in mice 3
(Date:6/19/2013)... are threatened with extinction as a result of rising human ... Ohio State University in the US. Their work is also ... human population will continue to pose a threat to other ... a threshold above which population growth would cease to have ... Springer,s journal, Human Ecology . , It has long ...
(Date:6/19/2013)... June 19, 2013 A decade-long JDRF-funded study ... Helmholtz Zentrum Mnchen, Germany, is providing a deeper ... risk of developing type 1 diabetes (T1D), highlighting ... for the disease. The study, "Seroconversion to Multiple ... in Children," was published today in The ...
(Date:6/19/2013)... ITHACA, N.Y. A Cornell University study offers further ... 4 million to 6 million years ago was profoundly ... in turning genes on and off. , The study, ... evidence for a 40-year-old hypothesis that regulation of genes ... is little difference between humans and chimps in the ...
Breaking Biology News(10 mins):Are we pushing animals over the edge? 2New data on islet autoantibodies in young children defines early type 1 diabetes development 2New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... NEW YORK Researchers at Columbia University Medical ... in microRNAs, a family of molecules that regulate ... behavioral and neuronal deficits associated with schizophrenia and ... 11 issue of Nature Genetics, Maria Karayiorgou, M.D., ...
... Java ... Compatibility, ... biometric identification technologies, today announced,the availability of MegaMatcher 2.1 SDK ... multi-biometric,face-fingerprint identification systems. MegaMatcher 2.1 includes a number,of new features ...
... of Amsterdam have discovered how to keep ones tomatoes ... level. The story of how the plant beat ... plant diseases, is published May 9th in the open-access ... continuously battling the ability of plant pathogens to co-evolve ...
Cached Biology News:Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs 2Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems 2Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems 3Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems 4
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... on coated slides. Sections are large (3-5mm ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5mm in diameter) ...
... Microdissection , CapSure HS and CapSure Macro ... extraction of populations of pure cells from ... Capture Microdissection., Ensure the Integrity of ... All CapSure LCM Caps have a patented ...
Biology Products: